Glychek-M OD Tablet is a combination oral hypoglycemic agent containing Gliclazide 60mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, which helps in reducing insulin resistance. The once-daily formulation of Glychek-M OD facilitates patient compliance by providing sustained glycemic control throughout the day. This combination is particularly beneficial for patients inadequately controlled on diet and exercise alone or those requiring dual therapy to achieve target blood glucose levels. Glychek-M OD should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular monitoring of blood glucose. Caution is advised in patients with renal impairment, hepatic dysfunction, or cardiovascular disease. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while hypoglycemia is primarily associated with the sulfonylurea component. Regular monitoring of blood glucose and renal function is recommended during therapy. Glychek-M OD offers an effective therapeutic option for optimizing glycemic control in type 2 diabetes mellitus.